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According to the authors and editors, this report contains the most justified principles of diagnostic and therapeutic 
procedures prepared considering the scientific value of evidence and category of recommendations. These principles 
should always be interpreted in the context of an individual clinical situation. The recommendations do not always 
correspond to the current reimbursement rules in Poland. In case of doubt, the current possibilities of reimbursement 
of individual procedures should be established.
1.  The quality of scientific evidence
 I — Scientific evidence obtained from well-designed and conducted randomized clinical trials or meta-analyses of 
randomized clinical trials
 II — Scientific evidence obtained from well-designed and conducted prospective observational studies (non-ran-
domized cohort studies)
 III — Scientific evidence obtained from retrospective observational studies or case-control studies
 IV — Scientific evidence obtained from clinical experiences and/or experts, opinions
2.  Category of recommendations
 A — Indications confirmed unambiguously and absolutely useful in clinical practice
 B — Indications probable and potentially useful indications in clinical practice
 C — Indications determined individually
Epidemiology and aetiology
Skin melanomas are malignant neoplasms deriving 
from neuroendocrine melanocytic cells. Melanoma are 
relatively rare in Poland — the standardised incidence 
rate reaches about 5/100,000, which represents 3600 new 
melanoma cases per year during the last few years 
(about 1800 men and about 1800 women). However, 
the incidence rate of melanoma is increasing rapidly 
compared to other neoplasms. A threefold increase of 
melanoma morbidity has been observed in Poland dur-
ing the years 1980 to 2010. The median age at diagnosis 
is similar for both sexes and equals about 50 years. The 
standardised mortality rate reaches 2.4/100,000 men and 
1.5/100,000 women, which represents, during the last 
years, respectively, about 760 and 680 melanoma-related 
deaths [1, 2].
The influence of the natural ultraviolet radiation 
(solar rays) and artificial radiation (e.g. tanning beds, 
solarium), permanent mechanical or chemical irrita-
tion, low content of pigment in the skin, and genetic 
predispositions (e.g. familial atypical mole syndrome; 
FAMS) constitute risk factors of melanomas.
Cutaneous melanoma has a unique chance to be 
cured due to its localisation, which enables early identi-
fication of the primary site (microstaging I — excisional 
biopsy of the primary lesion) and of the metastases to the 
locoregional lymph nodes (microstaging II — sentinel 
nodes biopsy).
In about 80% of patients, cutaneous melanoma 
is a limited, localised disease, while a loco-regional 
advanced or metastatic disease is primarily diagnosed 
in, respectively, 15% and 5% of patients. Progress in 
the adjuvant and palliative therapy of patients with 
metastatic melanoma is still unsatisfactory. The five-year 
overall survival rates reach in early stages of melanoma 
70–95% as well as 20–70% and 20–30% in regionally 
advanced and metastatic disease respectively with the 
use of modern systemic therapy. 
The crucial recommendation is to treat a melanoma 
patient with a multidisciplinary team formed by specialists 
experienced in diagnosing and treating melanoma [3, 4]. 
Diagnostics 
Clinical symptoms
Skin melanomas may be suspected in both de 
novo skin changes and in alterations of pre-existing 
moles. There have been some attempts to create diag-
nostic systems based on clinical symptoms (Table 1). The 
most popular of these is the American mnemonic clinical 
system called ABCD(E), used mostly with educational 
intent because it is useful only in identification of some 
melanomas, mostly of the superficial spreading melano-
mas and the majority of advanced melanomas. However, 
this system cannot be used as a diagnostic (screening) 
tool in daily clinical practice. A clinical ABCD(E) system 
does not permit appropriate qualification of about 50% of 
melanomas (especially including the early stages of skin 
melanomas with diameter < 5 mm, nodular melanoma 
usually without parameter C — heterogeneity of colour 
and B — irregular border as well as amelanotic melano-
mas and changes of the hairy skin of the head surface) [1]. 
Thin melanomas (< 1 mm of thickness according to 
Breslow scale) are usually identified during the medical 
examination, whereas very rarely by the patient their 
relatives. 
Diagnostics
Medical history should include questions concern-
ing skin condition (information concerning changes 
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Table 1. American ABCD(E) system, which enables the initial identification of a part of melanomas based on a clinical 
examination without use of any supplementary diagnostic methods
ABCD system
A — asymmetry (a melanoma, in contrast to usually round or ellipsoidal benign changes, is asymmetrical in relation to any 
axis. Melanoma presents as an uneven change composed of elevations called ‘islands’)
B — borders (irregular and unravelled)
C — colour (the presence of more than one colour [from bright brown to black or steel blue] or the uneven distribution of colour, 
often with spotted distribution of the pigment [especially visible on the dermatoscopy])
D — diameter (diameter > 5 mm or dynamics of the morphological sizes in a tumour)
E — elevation or evolution (elevation of surface over the level of the change surrounding epidermis. Thin melanomas 
[thickness ≤ 1 mm according to Breslow scale] do not form a palpable node compared to a normal skin surrounding the lesion; 
increase of the diameter [extension or evolution] of the primary change is more significant than its elevation)
of the pre-existing skin moles, the appearance of new 
pigmentary lesions, and accompanying symptoms, e.g. 
pruritus) and risk factors of cutaneous melanoma (e.g. 
sunburn, use of tanning beds, melanomas in relatives, 
and previous immunosuppressive treatment or HIV 
infection). It is important to stress that in more than 
60% of melanoma diagnosed after physical examination 
patients did not report any specific data in anamnesis, 
which can be helpful to establish this diagnosis. 
We should stress that whole skin examination is 
a crucial method of detecting skin melanomas and 
should be performed by each physician during the 
ambulatory visit or hospitalisation of any patient. The 
major rule of the visual inspection is to evaluate the 
total skin surface in appropriate lighting, also including 
the hard-to-reach areas (head, feet, interdigital spaces, 
urogenital, and perianal areas).
The recommended test, used in preliminary, quick, 
non-invasive diagnostics, is dermoscopy (dermatoscopy) 
(II, A) [5, 6]. The examination consists of assessment of 
all lesions on the patient’s skin by means of a manual 
dermoscope with polarised or non-polarised light with 
10 x magnification [6]. Thanks to dermoscopy it is pos-
sible to improve the diagnostic sensitivity by about 30%. 
The simplest technique of dermoscopic assessment (the 
so-called three-point dermoscopic scale according to 
Argenziano) is based on the clinical suspicion of mela-
noma when two of the following three criteria are met: 
1) asymmetric distribution of the dermoscopic structures 
within the change, 2) atypical pigmentation network, 
and 3) blue-white veil. The sensitivity of this diagnostic 
method reaches 96.3% and specificity 94.2%. Other 
methods of dermatoscopic analysis including the derma-
toscopic method ABCD, pattern analysis, seven-point 
scale, Menzies’s method, or CASH (colour, architecture, 
symmetry, homogeneity) algorithm are characterised by 
similar sensitivity and slightly higher specificity. It should 
be stressed that the presented dermatoscopic evaluation 
systems cannot be used to assess lesions placed in ‘special 
locations’ including changes of palms and soles of the feet, 
the hairy skin of the head surface, the skin of the face, 
mucosa of the mouth, and the external sex organs. In such 
cases it is necessary to apply dermatoscopic algorithms, 
dedicated to the character of the skin of each localisation. 
In the case of atypical mole syndrome, it may be useful to 
collect photographic records of a lesion or of the total skin 
surface (total body photography) and to compare taken 
pictures and observed skin lesions in consecutive time 
sequences. There are some systems that automatically 
compare dermatoscopic pictures taken in different time 
sequences; however, they are not commonly used due to 
their technological limitations. 
An initial dermatoscopic diagnosis may by verified by 
use of the confocal reflection microscopy. In some justi-
fied cases when an excisional biopsy cannot be performed 
(e.g. when melanoma is suspected in the area of the ex-
tensive congenital moles in small children), it is possible 
to perform a dermatoscopy-guided biopsy in order to 
obtain a sample for further histopathological examination. 
Histopathological examination of the whole excised 
mole is crucial for diagnosing a skin melanoma. Proce-
dures other than excisional biopsy (microstaging I) do 
not permit an appropriate diagnosis (III, A).
Once a histopathological diagnosis of a skin mela-
noma has been made a clinical stage tailored therapy 
should be implemented (see below). 
The supplementary diagnostic tests used in clinical 
staging of the melanoma include: essential blood test 
[peripheral blood morphology, liver enzymes levels, lactate 
dehydrogenase (LDH) activity], radiologic exam (RTG) of 
the chest in an anteroposterior and in lateral projection, 
as well as the ultrasonographic exam of the abdomen and 
of the locoregional lymph nodes. First of all, a thorough 
physical examination should be carried out, including the 
examination of the whole skin (presence of other suspi-
cious pigmented lesions, satellite and / or in transit chang-
es), assessment of lymph nodes, and examination for the 
presence of possible distant metastasis. In low-risk clinical 
melanomas (pT1a), other tests are not routinely required. 
However, in higher stages (pT1b–pT3a), a scan should be 
performed by ultrasound examination of regional lymph 
nodes, and a suspected biopsy should be performed with 
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Table 2. Clinical differential diagnostics ofcutaneous melanoma
Early skin melanoma — Pigmented naevus, including junction nevus (naevus melanocyticus junctionalis, marginalis)  
and compound nevus (naevus melanocyticus compositus)
— Blue nevus (naevus coeruleus)
— Simple lentigo (lentigo simplex)
— Actinic keratosis or solar keratosis 
— Superficial basal cell carcinoma (carcinoma basocellulare superficiale) 
— Spitz’s naevus
— Tattoo
Locally advanced 
melanoma
— Seborrheic keratosis (verruca seborrhoica, keratosis seborrhoica)
— Dermatofibroma
— Keratoacanthoma
— Pigmented basal cell carcinoma (carcinoma basocellulare pigmentosum)
— Haemangioma 
— Venous extravasation
— Pyogenic granuloma (granuloma pyogenicum) and telangiectatic granuloma 
(granuloma telangiectaticum)
— Pigmented hidrocystoma
— Kaposi’s sarcoma 
— Angiomyoneuroma
— Other adnexal tumours, especially pigmented
— Onychomycosis
— Subungual or under cutaneous corn haemangioma 
a histological evaluation before the scar is removed and 
the sentinel node biopsy is performed. In patients without 
symptoms, there is no need to perform other additional 
tests, which mainly concerns computed tomography of 
the brain, chest, abdominal cavity and pelvis with contrast 
(CT) and positron emission tomography (PET). CT or 
PET may be considered in patients with diagnosed skin 
melanoma in clinical stage IIC and III (especially if the 
clinical metastases to the lymph nodes are present) or 
with isolated metastases to the distant organs. In the case 
of the clinical metastases to the inguinal lymph nodes it 
is recommended that CT or magnetic resonance imaging 
(MRI) of the pelvis and abdomen be performed. 
In patients with melanoma metastases from an 
unknown primary site to the lymph nodes or to the 
skin, a primary lesion should be searched for carefully 
(especially on the hairy skin of the head surface and the 
mucosal membranes) and a detailed medical history 
taken (e.g. concerning any cosmetic medicine ablation 
methods applied to any lesion).
Differentiation
The conditions that should be considered in the dif-
ferential diagnostics of early and locally advanced skin 
melanoma are presented in Table 2.
Histopathological diagnosis — excisional biopsy of 
the skin lesion (microstaging I)
An excisional biopsy of the clinically suspected skin 
lesion is a method of choice because it allows confir-
mation of a microscopic diagnosis of melanoma and 
collection of data concerning the crucial risk factors, 
crucial for planning a further therapeutic approach 
(microstaging) (III, A) [1, 3, 4, 7]. There are no indica-
tions for prophylactic excision of skin moles that are not 
suspected of being skin melanoma. 
Pathomorphological examination of samples from 
the excisional biopsy consists of macro- and microscopic 
assessment of all elements that are required or recom-
mended for examination and inclusion in the histopatho-
logical protocol (http:/www.pol-pat.pl/pliki/files/stand-
ardy_pdf/1.2_czerniak.pdg):
1. Macroscopic assessment 
a. Size of the excised skin section with the lesion 
(three dimensions);
b. Size of the lesion (two dimensions);
c. Pigmentation (homogenous, heterogeneous);
d. Border of the lesion (regular, irregular);
e. Nodule (present, not present);
f. Margins (lateral and deep margin).
2. Microscopic assessment 
Microscopic features/characteristics that are required:
a. Breslow thickness of infiltration (in millime-
tres) is measured from the top of the granular 
layer of the epidermis, or if the surface is 
ulcerated — from the base of the ulcer, to the 
deepest invasive cell across the broad base of 
the tumour;
b. Presence or absence of ulceration including the 
whole thickness of the epidermis covering the 
tumour as well as information about the extent 
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of ulceration, measured either as the diameter 
or percentage of tumour width;
c. Mitotic count per square millimetre of the in-
vasive melanoma (only in a vertical component, 
in the mitotic high-power fields that equates to 
1 mm2, so-called hot spots);
d. Growth phases (horizontal [radial] — intraepi-
dermal, in situ with microinvasion and sagittal 
[vertical], always skin invasion);
e. Presence or absence of microscopic satellite 
sites (sites composed of melanocytes with dia-
meter > 0.05 mm remoted > 0.3 mm and < 2 cm 
from the invasive component of the primary 
melanoma tumour — parameter N). 
f. Peripheral margin (measured from the in situ to 
the invasive component) and in depth;
g. Clinical stage pT;
Recommended elements:
h. Presence and extend of tumour regression;
i. Clark level of invasion (level I, II, III, IV, V);
j. Histopathological subtype (superficial spreading 
melanoma [SSM], lentigo maligna melanoma 
[LMM]; arising from a lentigo or in a Hutchinson 
age spot, nodular melanoma [NM], acral len-
tiginous melanoma [ALM] — subungual, other 
types — e.g. desmoplastic); 
k. Cell type (epithelioid, fusiform, small, pleomor-
phic, other); 
l. Presence and grading of the lymphocytic infiltra-
tion (tumour infiltrating lymphocytes [TILs]; eval-
uated only in a vertical component; absent, moder-
ate — TILs non-brisk, abundant — TILS brisk);
m. Presence or absence of lymph and blood ves-
sel infiltration;
n. Presence or absence of nerve trunk infiltration; 
o. Presence of a mole.
WHO classification of skin tumours 4th Edition 
2018 distinguishes the following types of melanoma [8]:
•	 melanocytic tumours in intermittently sun-exposed skin;
 — superficial spreading melanoma, low-SCD mela-
noma);
•	 melanocytic tumours in chronically sun-exposed skin;
 — lentigo maligna melanoma;
 — desmoplastic melanoma;
•	 Spitz melanoma;
•	 acral melanoma;
•	 mucosal melanoma;
 — mucosal lentiginous melanoma;
 — mucosal nodular melanoma;
•	 melanoma arising in blue naevus;
•	 melanoma arising in giant congenital naevus;
•	 ocular melanocytic tumours;
 — uveal melanoma (epithelioid cell melanoma, 
spindle cell melanoma type A, spindle cell mela-
noma type B);
 — conjunctival melanoma;
•	 nodular melanoma, naevoid melanoma, and meta-
static melanoma.
An excisional biopsy is a simple surgical procedure that 
can usually be performed in an outpatient clinic. Excision 
of the suspected skin change is done in local infiltration 
anaesthesia. The lateral excision margin should include 
1–2 mm of healthy skin. The surgical specimen should 
include not only the whole thickness of the skin but also 
a superficial layer of the adipose tissue. The fascia should 
not be excised, and the wound should be closed by a pri-
mary suture. The skin should be cut as an ellipse speci-
men following the lines of relaxed skin tension (Fig. 1). 
Only the cut of the face lesion should follow the aesthetic 
lines. Transversal cuts should never be done (on the limb 
area) because in the case of repeated surgery they give 
a poor cosmetic effect and are inconsistent with oncologi-
cal recommendations. 
Results of fine- or core-needle aspiration biopsy or 
of the incisional (section) or shave biopsy do not deliver 
reliable data (according to recommendations of the 
American Joint Cancer Committee/Union International 
Contre le Cancer [AJCC/UICC]) concerning the pri-
mary melanoma lesion and therefore should not be used. 
If the lesion is extensive and ulcerated, imprint cyto-
logy may be performed in order to obtain a sample for 
cytological examination (a glass slide should be pressed 
onto the tumour surface and then the material should 
be referred to cytological examination).
It is currently known that some defined subtypes of 
melanoma are associated with specific mutations (e.g. 
 
 
 
Local anaesthesia 
Minimal margin 1–3 mm
Extremities — the longest 
axis in the axis od extremity 
parallel to the lymphatic 
vessels 
Lymphatic vessels
The entire lesion sent
for pathological 
examination 
Excisional biopsy — technique
Figure 1. (According to W. Ruka) Recommended direction of 
the cut during the excisional biopsy. Spindle-shaped excision 
of the suspected pigmentary lesion should be made collaterally 
to the regional lymph vessel (toward the nearest draining 
lymph node/lymph vessel confluence), in the majority of cases 
enabling a primary suture of the wound
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KIT gene mutations — subungual melanoma or mucosa 
melanomas). In patients with disseminated (primary or 
secondary) melanoma, testing for BRAF gene muta-
tion in the FFPE is obligatory in the case of high risk 
of relapse of melanoma (clinical stage IIIA > 1 mm, 
IIIB, IIIC and IIID) and for KIT and NRAS mutation is 
optional (V, A). There is no need for repeated sampling 
of the metastases to detect the presence of molecular 
disorders. Genetic tests should be performed in refer-
ral centres that undergo quality audits. It is not recom-
mended that mutations are tested for inpatients with 
skin melanoma and no metastatic sites [4]. 
Sentinel node biopsy (microstaging II)
A sentinel node biopsy should be done in patients 
(II, A) [1, 3, 4, 9, 10]:
 — after an excisional biopsy and with histopatho-
logical confirmation of skin melanoma but not 
after a wide local excision of a primary site;
 — with Breslow thickness ≥ 0.8 mm or with (micro-)
ulceration on the melanoma surface indepen-
dently of the thickness of the infiltration (mela-
noma with primary site that has been classified 
as pT1b–T4b according to TNM UICC/AJCC 
2017 classification); according to recommenda-
tions of the American Society of Surgical On-
cology (SSO), the American Society of Clinical 
Oncology, and the European Society of Medical 
Oncology (ESMO), a sentinel node biopsy may 
be considered in melanoma pT1b and thickness 
0.8–1.0 mm and coexistence of additional risk 
factors, e.g. mitotic index ≥ 1/mm2 (III, A);
 — without clinical symptoms of metastases to the 
regional lymph nodes or to the distant organs.
A sentinel node biopsy is obligatory to assess the 
presence of micrometastases in the lymph nodes [11]. 
During the sentinel node biopsy, a preoperative lym-
phoscintigraphy and a intraoperative lymphoscintigra-
phy combined with staining should be done. A sentinel 
node biopsy should be performed after the excisional 
biopsy of melanoma, simultaneously with radical, wide 
local excision of the scar after the primary excisional 
biopsy of melanoma. Accessible data do not indicate any 
negative prognostic impact of performing the sentinel 
node biopsy six weeks after the excision of the primary 
melanoma site (III, B). The accuracy of this method 
depends on the cooperation of a nuclear medicine spe-
cialist, surgeon, and pathologist. A sentinel node biopsy 
is a diagnostic procedure that is ‘minimally invasive’ due 
to low frequency of early and late complications. 
All detected lymph nodes should undergo patho-
physiological assessment. If the metastatic deposits are 
macroscopically visible, it is enough to exam only one 
section, while in all other cases serial sections of the 
lymph node at every 2–4 mm should be done. A his-
topathological report describing this material should 
include the number of lymph nodes found, the number 
of lymph nodes with metastases, the size and localisation 
of the biggest metastatic site, the presence or absence of 
the extracapsular spreading, and vascular invasion. Im-
munohistochemical exam with use of specific markers 
(e.g. HMB45, Melan-A) may visualise tiny conglomerates 
of the neoplastic cells.
The results of the prospective study Multicentre 
Selective Lymphadenectomy Trial 1 (MSLT-1) suggest 
that a sentinel node biopsy melanoma helps to identify 
patients with high risk of metastases, helps to assess 
the clinical stage of the disease, ensures excellent local 
disease control, and enables qualification of patients to 
clinical trials with the use of homogenous criteria [9]. 
In the MSLT-1 trial in the whole analysed population 
of patients who underwent sentinel node biopsy, no 
disease-free survival time and no overall survival time 
improvement was proven, compared to the whole study 
population. However, in a subgroup of patients with 
present metastases to lymph nodes the overall 10-year 
survival rate was significantly better in patients in whom 
an immediate lymphadenectomy had been performed in 
the case of a positive sentinel node, compared to patients 
who had received this therapy later for clinically overt 
metastases (62.1% vs. 41.5%; p = 0.006) [9].
If the histopathological assessment affirms the 
presence of melanoma metastases to sentinel nodes, 
a radical lymphadenectomy may be considered (so-called 
completion lymph node dissection, CLND) because the 
melanoma metastases to other lymph nodes are detected 
by routine histopathological methods in about 20–30% 
of patients [12] (especially when micrometastasis size 
exceeds 1 mm). An alternative option is an observation 
with use of ultrasonographic monitoring of the regional 
lymphatic basin every 4–6 months. The results of two 
published randomised studies [13, 14] did not prove any 
survival benefit in patients who had CLND due to a posi-
tive sentinel node biopsy. However, an improvement in 
regional lymphatic basin control was achieved. Crucial 
prognostic value of the sentinel node biopsy was also 
confirmed in these studies. 
There are ongoing clinical studies evaluating if the 
adjuvant lymphadenectomy may be limited in some 
patients (sub-micrometastases to the sentinel lymph 
node with diameter < 0.1 mm or placed subcapsular 
and with diameter < 0.4 mm) with no negative impact 
on the melanoma reoccurrence rate [15].
Staging and risk factors
Identification of the clinical and pathomorphological 
risk factors is aimed at understanding the biology of the 
neoplasm and planning a tailored therapy for a given 
patient, which considers relapse risk factors and overall 
survival probability. 
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Table 3. Clinical staging classification according to TNM AJCC/UICC from the year 2017
A. TNM system categories
Parameter T Breslow thickness [mm] (Micro-)ulceration
pTis (in situ)
T1 
    T1a
    T1b
≤ 1.0
< 0.8
< 0.8
0.8–1.0
Without ulceration
With ulceration
With or without ulceration
T2
    T2a
    T2b
> 1.0–2.00 Unknown or undetermined 
a) Without ulceration
b) With ulceration
T3
    T3a
    T3b
> 2.0–4.0 Unknown or undetermined 
a) Without ulceration 
b) With ulceration
T4
    T4a
    T4b
> 4.0 Unknown or undetermined 
a) Without ulceration 
b) With ulceration
Parameter N Number of the regional lymph nodes with metastases Presence of an in-transit 
metastasis, satellite sites and/or 
microsatellite***
Nx The status of the regional lymph nodes cannot be assessed No
N0 0 No 
N1
    N1a
    N1b
    N1c
One lymph node with metastatic transformation or presence of 
in-transit metastases satellite and/or microsatellite foci without 
involvement of the lymph nodes 
Metastasis to one lymph node detected by sentinel biopsy 
(micrometastasis*) 
Metastasis to one lymph node assessed by clinical exam 
(macrometastasis**)
No metastases to regional lymph nodes 
No
No
Yes
N2
    N2a
    N2b
    N2c
Micrometastases to 2 or 3 lymph nodes
Metastases to 2 or 3 lymph nodes, at least one clinically involved 
Metastasis to 1 lymph node (assessed by sentinel lymph node biopsy  
or clinically) 
No
No
Yes
N3
    N3a
    N3b
    N3c
≥ 4 lymph nodes or a conglomerate of lymph nodes or in-transit/satellite 
changes with coexisting metastases to at least lymph nodes
Micrometastases to at least 4 lymph nodes 
Metastases to at least 4 lymph nodes and at least one as clinically overt 
or conglomerate of lymph nodes 
Metastases to 2 or more lymph nodes and/or conglomerate of lymph 
nodes 
No
No
Yes
Parameter M Localisation of the metastases Serum LDH activity
M0 Without distant metastases 
M1a 
    M1a(0)
    M1a(1)
Skin, subcutaneous tissue, or non-regional lymph nodes 
Normal
Increased 
Risk (prognostic) factors
The primary melanoma lesion
The most important risk factors in patients with skin 
melanomas without metastases are thickness (Breslow) 
and the presence of micro(ulceration) of the primary 
site. An important prognostic value of mitotic index and 
microsatellitosis as part of parameter N has recently 
been proven. These factors are included in TNM system 
version 8 (Table 3) [4, 7, 11, 16].
Æ
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M1b
    M1b(0)
    M1b(1)
Lungs ± localisations M1a
Normal
Increased 
M1c
    M1c(0)
    M1c(1)
Other than above mentioned visceral organs with exclusion of central 
nervous system and ± localisations M1a and M1b  
Normal
Increased
M1d
 
    M1d(0)
    M1d(1)
Metastases to the central nervous system ± localisations M1a,  
M1b or M1c 
Normal
Increased
*Micrometastasis to the lymph node — detected by the microscopic exam of the clinically asymptomatic (not enlarged) lymph node, after performing the 
sentinel node biopsy; **macrometastasis to the lymph node — confirmed by the microscopic exam of the clinically palpable lymph node (enlarged) after 
a therapeutic lymphadenectomy; ***micro-/satellitosis — neoplastic infiltration or nodules (macro or microscopic) remoted up to 2 cm from the primary site 
of the skin melanoma to the level of the nearest regional lymph confluence/drainage; LDH — lactate dehydrogenase
B. Clinical stages 
Clinical stages* Pathological stages**
T N M T N M
0 Tis N0 M0 Tis N0 M0
IA T1a N0 M0 T1a
T1b
N0
N0
M0
M0
IB T1b
T2a
N0
N0
M0
M0
T2a N0 M0
IIA T2b
T3a
N0
N0
M0
M0
T2b
T3a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
T3b
T4a
N0
N0
M0
M0
IIC T4b N0 M0 T4b N0 M0
III*** Any T N1
N2
N3
M0
IIIA T1a/b–T2a N1a
N2a
M0
M0
IIIB T0
T1a/b–T2a 
T2b/T3a
N1b/N1c
N1b/c or 
N2b
N1a–N2b
M0
M0
M0
IIIC T0
T1a–T3a
T3b/T4a
T4b
N2b, N2c, 
N3b or N3c
N2c or 
N3a/b/c
Any N ≥ N1
N1a–N2c
M0
M0
M0
M0
IIID T4b N3a/b/c M0
IV Any T Any N Any M1 Any T Any N Any M1
*Clinical staging includes micrograding of the primary site and a clinical/radiological assessment of presence of metastases. Consequently, clinical staging 
may be applied only after complete excision of the primary site of the skin melanoma (excisional biopsy) and evaluation of the regional lymph nodes and 
distant organs for the presence of metastases; **pathologic grading/staging includes micrograding of the primary site and a pathological assessment of the 
regional lymph nodes: after a sentinel lymph node biopsy or after a radical lymphadenectomy (except from stage 0 and IA in which no procedure is applied 
to the regional lymph nodes); ***clinical staging does not include any subgroups of stage III
Table 3 (cont.). Clinical staging classification according to TNM AJCC/UICC from the year 2017
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Metastases to the regional lymph nodes (clinical 
stage III)
The presence of metastases in the regional lymph 
nodes is the most important prognostic factor in pa-
tients with skin melanomas. In the case of the presence 
of metastases, the number of involved regional lymph 
nodes constitutes the principal risk factor. The type of 
metastases also influences the risk; patients with mi-
crometastases have better prognosis (neoplastic sites 
detected during the microscopic exam in the clinically 
not enlarged and not palpable lymph nodes — excised 
during the sentinel node biopsy) than patients with 
macrometastases (foci of neoplasm diagnosed during the 
microscopic exam in a clinically enlarged and palpable 
lymph node). Extracapsular infiltration of the neoplastic 
cells constitutes an additional negative risk factor in 
patients with metastases to the lymph nodes.
Metastases to the distant organs (clinical stage IV)
Localisation of metastases and LDH activity are the 
major prognostic factors in patients with extra nodal me-
tastases. The worst prognosis in this group of patients is 
with metastases to the central nervous system
Clinical staging — classification
The actual clinical and pathological stage classification 
system of skin melanoma according to TNM was revised 
in 2010 and 2017, and formulated based on the multifactor 
analysis of the data of 38,000 patients (Table 3) (II, A) [16].
Treatment
Surgery is a treatment by choice in patients with mela-
noma (I, A). After performing an excisional biopsy of the 
suspected pigmented lesion and making a diagnosis of 
melanoma, we should consider a wide scar excision with 
appropriate margins and a sentinel node biopsy (Figure 2). 
In the case of detecting a metastasis in clinically palpable 
reginal lymph nodes by fine-needle biopsy, lymphadenec-
tomy of the regional lymph nodes should be performed. 
Lymphadenectomy should be considered if a sentinel node 
biopsy confirms metastases. In fact, adjuvant therapy after 
surgery is used only in special situations, and in patients 
with metastatic disease it should be tailored to the clinical 
situation. The essential and obligatory recommendation 
is to refer patients to a multidisciplinary team of special-
ists experienced in diagnostics and treating melanomas.
Surgical treatment
Primary site
Radical therapy of the primary site of melanoma 
includes a radical wide excision of the scar after the 
excisional biopsy of the primary site.
Based on the results of six multicentre, randomised 
trials it was decided to derogate from extended excisions 
of the primary melanoma site (with margin ≥ 3 cm) in 
favour of narrower margins of healthy tissues. The fol-
lowing are the current recommended margins of radical 
therapy of the primary melanoma lesion (excision of the 
scare after excisional biopsy of the primary site): mela-
noma in situ — margin 5 mm, melanoma with tumour 
depth ≤ 2 mm — margin 1 cm, and melanoma with 
tumour depth > 2 mm — margin 2 cm (Table 4) (II, A).
Applying margins wider than 2 cm decreases the 
local reoccurrence rate but does not improve long-term 
survival. The scar after an excisional biopsy of a mela-
noma ≤ 2 mm should be removed without superficial 
fascia. These rules cannot be applied for melanomas 
located on the face, where no fascia is present and the 
excision margin may be narrower. In the case of the 
subungual localisation of melanomas, a distant phalanx 
should be amputated. 
Regional lymph nodes
Patients with melanoma with metastases to the re-
gional lymph nodes are a heterogenous group of patients 
considering the prognosis (five-year survival range: 
15–70%). Prospective clinical trials did not confirm any 
benefit of performing an elective lymphadenectomy in 
patients without clinical signs of melanoma metastases 
to the lymph nodes. Currently, lymphadenectomy in 
patients with cutaneous melanomas is performed only 
in the case of metastases on the basis of examination of 
the material collected by fine-needle biopsy (in special 
cases — surgical biopsy) from enlarged and clinically 
suspected lymph nodes or in some cases in the confir-
mation of the presence of metastasis in sentinel nodes 
unsuspected clinically (microstaging II) [1, 3, 9, 17].
Therapeutic lymphadenectomy 
Qualification of patients for lymphadenectomy 
should be based on a clinical exam, laboratory test (in-
cluding LDH serum level), and imaging techniques. If 
the metastases to distant organs are suspected, a pa-
tient should have computed tomography or PET-CT 
(especially of the pelvis when metastases to the iliac 
and obturator lymph nodes are suspected) and MRI. 
Imaging exam of the central nervous system should be 
performed in the case of occurrence of clinical symptoms 
and in stage IIIC. 
The extent of the therapeutic lymphadenectomy in 
skin melanoma is as follows (III, C): 
 — in the axilla all lymph nodes should be removed ac-
cording to the anatomic definition (three groups of 
lymph nodes and the surrounding fascia: lower com-
partment — pectoral [anterior] and subscapular [lat-
eral] lymph nodes, central compartment — central 
axillary lymph nodes, upper compartment — infra-
clavicular [deltopectoral] and apical lymph nodes);
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ABCD(E) system 
A  Asymmetrical Shape
B  Border
C  Colour
D  Diameter
E  Evolution (or change)
History and physical 
examination; 
dermoscopy
A suspicious 
pigmented lesion
Additional 
tests
Excisional biopsy 
(a margin of 1–3 mm)
— microstaging I
Benign lesion 
= observation
Skin melanoma
TNM
Thickness < 0.8 mm;
stage pT1a
Thickness ³ 0.8 mm;                    
micro-ulceration (³ pT1b)
Radical excision 
of the scar after 
excisional biopsy Sentinel lymph node biopsy
— microstaging II
Clinical follow-up: 
"wait and see"
Local recurrence, 
metastasis in-transit Palpable lymph 
nodes
Surgery, isolated limb 
perfusion, radiotherapy, 
electrochemotherapy, T-VEC, 
systemic treatment
Metastases other
FNA, 
histopathology
Negative
Positive
Follow-up
Positive Negative
Close follow-up with lymph nodes basin 
ultrasound or optional lymphadenectomy 
at high risk
Lymphadenectomy
Follow-up
Adjuvant treatment: anti-PD-1 immunotherapy 
or treatment with anti-BRAF/MEK for one year; clinical trials, 
radiotherapy in individualised cases
1. Surgery
2. Radiotherapy
3. Chemotherapy**
4. BRAF inhibitor (BRAF+*) + MEK 
inhibitor
nd5. Ipilimumab (2  line, good 
performance) mainly at BRAF–
6. Anti-PD-1 antibodies 
(pembrolizumab or nivolumab)
7. Anti-PD-1 + anti-CTLA-4 antibodies
8. Clinical trials
*BRAF mutation analysis obligatory in case of diagnosis of distant metastases eligible for systemic treatment and in grade III for qualification 
for adjuvant treatment
**Never in the first line
Figure 2. A  schedule of diagnostic and therapeutic recommendations in patients with skin melanoma. FNA — fine-needle 
aspiration biopsy; TNM (tumour–node–metastasis) — classification of tumour/node/metastasis stage
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 — in the groin we should remove the lymph nodes of 
the inguinal-femoral lymph nodes located below the 
inguinal ligament in the femoral triangle together 
with the femoral fascia, iliac lymph nodes placed 
along the external iliac vessels (optionally also inter-
nal and common), as well as the lymph nodes of the 
obturator fossa (in the case of metastases diagnosed 
in the sentinel nodes the lymphadenectomy should 
be restricted to inguinal lymph nodes); 
 — in the cervical lymphatic confluence modified pro-
cedures may be applied. These procedures must 
be maximally radical. Usually the neck structures 
that contain superficial lymph nodes (anterior and 
posterior) and profound are dissected in one piece, 
limited posteriorly by profound jugular facia and 
frontally by the platysma muscle. 
Sometimes it is necessary to perform lymphadenec-
tomy in the popliteal or ulnar fossa.
Local reoccurrence and in-transit metastases 
Terms: satellitosis (micro- or macroscopic), local re-
occurrence, and in-transit metastases form a kind of con-
tinuity and represent different forms of one pathologic 
phenomenon. Usually a local reoccurrence (often even 
after a very wide excision of the primary site) represents 
spreading of melanomas through the regional lymphatic 
vessels (microsatellites become macrosatellites), which 
may then transform into in-transit metastases. That is 
why in the majority of elaborates the above-mentioned 
forms of relapse of melanoma are analysed together and 
have similar prognosis (10-year survival about 20–30%). 
Surgery is an essential method to treat a local relapse 
and in-transit metastases. Therapy should be individu-
alised and should consider the number metastases, their 
size, localisation, and clinical course (III, B). In the case 
of in-transit metastases surgical therapy includes exci-
sion of the countable changes (< 10) with a microscopic 
melanoma infiltration-free margin (it may be macro-
scopically narrow). In the case of a single relapse lesion 
Table 4. Summary of the recommendations of the National 
Comprehensive Cancer Network (NCCN) v. 3.2016, 
European Organisation for Research and Treatment of 
Cancer (EORTC), and the European Society of Medical 
Oncology (ESMO) concerning the final margin of the radical 
excision of the primary melanoma site depending on the 
Breslow thickness
Melanoma thickness  
(Breslow)
Recommended clinical 
margin 
In situ 0.5 cm
≤ 2.0 mm 1 cm
> 2.0 mm 2 cm
another sentinel lymph node biopsy may be considered. 
In the case of in-transit dissemination of melanoma limb 
amputation is not recommended. In the case of multi-
ple/non-resectable lesions one of the local therapeutic 
methods should be considered (ablation, radiotherapy, 
cryotherapy), intratumoural immunotherapy (talimo-
gene laherparepvec — T-VEC, PV-10 or interleukin-2) 
or local immunotherapy (imiquimod is not registered 
for this indication) and electrochemotherapy (III, B) 
or systemic therapy. In the case of extensive, multiple 
lesions located on the limb an hyperthermic isolated 
limb perfusion chemotherapy is a method of choice 
(HILP), mostly with use of melphalan. This method 
may be used only by experienced and trained centres. If 
HILP is contraindicated, systemic therapy should be 
administered [1, 4, 7, 17–19].
Adjuvant therapy 
Currently, dabrafenib with trametinib, pembroli-
zumab and nivolumab (the latter also after grade IV 
metastasectomy) are registered for systemic adjuvant 
treatment in clinical practice in patients after radical 
primary surgery and lymphadenectomy, and comple-
mentary radiotherapy may only be considered in very 
specific situations. The results of some recently published 
clinical studies indicate an improvement of survival rates 
after both adjuvant immunotherapy with use of immune 
checkpoint inhibitors and combined therapy with BRAF 
and MEK inhibitors (I, B).
High doses of interferon a-2b (INF a-2b) have been 
registered based on the positive result of one of three 
clinical studies by the Easter Cooperative Oncology 
Group (ECOG) — ECOG 1684 — in the United States of 
America and in the European Community — to treat pa-
tients with melanoma in clinical stage IIB–III. Low-dose 
INF a-2b has been registered in Europe for patients with 
clinical stage II melanoma [20, 21]. The registration was 
based on the significant prolongation of the overall sur-
vival during a seven-year observation time. These results 
have not been proven during a longer observation time 
(12 years). The results of the studies showed a repeatable 
(10 from 17 studies) improvement in the disease-free sur-
vival rates. The recent meta-analysis showed a significant 
decrease by 17–18% of the relative disease relapse risk 
after the administration of the adjuvant therapy with use 
of INF a-2b. The clinical evidence concerning overall 
survival rates is weaker and is based mostly on the results 
of meta-analyses. The overall five-year survival benefit 
for the whole group of patients reaches about 3–5%. The 
use of adjuvant therapy with INF a-2b in patients with 
intermediate and high relapse risk melanomas should be 
individualised due to its controversial clinical value and 
toxicity (II, B). The results of meta-analyses show that 
an adjuvant therapy with INF a-2b may be beneficial in 
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patients with ulcerated primary melanoma lesion, espe-
cially with coexistent micrometastases (to the sentinel 
node but with absence of metastases to the clinically 
enlarged lymph nodes) (I, B) [22, 23].
Ipilimumab is registered in the United Stated for ad-
juvant therapy of patients after lymphadenectomy of in-
volved regional lymph nodes. Randomised clinical trials 
[24] showed a significant improvement of disease-free 
survival and overall survival but with high toxicity of 
ipilimumab therapy (II, B) [25]. 
Nivolumab in a randomised study in patients after 
stage IIIB, IIIC, and IV metastases showed a 10% 
improvement in recurrence-free survival compared to 
ipilimumab with lower toxicity (I, A), which is now a reg-
istered indication [24]. Updated data from 2018 with 
a longer follow-up period confirm the beneficial effect 
of nivolumab in adjuvant treatment for a year regardless 
of the PD-L1 expression status and BRAF mutation with 
respect to RFS (HR 0.66) and DMFS (HR 0.76) [26]. 
Dabrafenib treatment with trametinib in patients with 
high-risk grade III BRAF (grade IIIA > 1 mm, IIIB/C) 
showed an improvement in recurrence-free survival 
and overall survival compared to placebo (I, A) [27, 
28]. The results of the Keynote-054/EORTC 1325 study 
in 1019 patients also indicate a reduction in the risk of 
recurrence (HR for RFS 0.57) and DMFS using pem-
brolizumab adjuvant treatment for one year, compared 
to placebo, in patients with grade III resection risk (IIIA 
with micrometers > 1 mm, IIIB and IIIC) (I, B) [29]. 
This indicates the need for an absolute multidisciplinary 
evaluation of all patients with melanoma in stage II–IV.
Other methods of immunotherapy (e.g. interleu-
kin-2), vaccines, or cytotoxic drugs have no clinical value 
in the adjuvant, postoperative therapy of melanomas.
In some individual cases, after surgical therapy of 
high-risk melanomas, an adjuvant radiotherapy (RT) 
may be applied. A dosing schedule includes — depend-
ing on the localisation of the melanoma lesion — hy-
pofractionation, 3–8 Gy per fraction, or conventional 
fractioning. Indications for adjuvant radiotherapy af-
ter the primary tumour excision include: diagnosis of 
desmoplastic melanoma excited with narrow margins, 
presence of ‘positive’ surgical margins (especially after 
excision of the local reoccurrence), presence of satellite 
foci, significant neurotropism, or head and neck region 
localisation (solo RT may be used for extensive LMM 
lesions). In the case of excision of local reoccurrence 
and lymphadenectomy due to metastases to the regional 
lymph nodes, indications for adjuvant RT are: pres-
ence of extracapsular node infiltrations, involvement 
of ≥ 4 lymph nodes (clinical stage IIIC), diameter of 
a metastasis > 3 cm, detection of metastases to cervical 
lymph nodes (from two metastatic lymph nodes or when 
a metastasis measures at least 2 cm), and reoccurrence 
after prior resection [30, 31]. The results of the only 
completed randomised clinical trial assessing the value 
of adjuvant RT (48 Gy in 20 fractions) after lymphad-
enectomy in the case of high-relapse-risk melanoma 
confirmed the improvement of local control in patients 
receiving radiation. RT had no impact on overall survival 
rate and resulted in a higher ratio of locoregional com-
plications and deterioration of patients’ quality of life. 
These results suggest that use of adjuvant RT should be 
limited (II, C) [32]. No adjuvant RT should be applied 
after CLND.
Therapy of patients with advanced disease 
The results of treatment of skin melanomas in clini-
cal stage IV are still unsatisfactory. The median overall 
survival time exceeds 12 months (and is significantly 
higher for new therapies), but about 20–30% of patient 
survive for five years. 
The significant prognostic factors in patients with 
melanoma in clinical stage IV are: performance status, 
LDH activity, and localisation of the metastatic le-
sions. In the case of qualification of a patient with clini-
cal stage IV melanoma for surgery or systemic therapy, 
disease should be staged by imaging exams or PET-CT 
(only in the case of isolated metastatic foci qualified 
for resection) [1].
In the case of secondary changes to the skin, soft tis-
sues, and non-regional lymph nodes (M1a, better prog-
nosis), it is always recommended to consider excision. 
A similar approach should be applied for isolated (not 
necessarily single) metastases to the visceral organs. In 
the case of unresectable lesions, the choice of therapeu-
tic approach depends on the presence of metastases to 
the central nervous system (CNS). If the metastases to 
the CNS are present neurosurgical treatment and/or 
radiotherapy of the central nervous system (usually ste-
reotactic or radiosurgery [33]) should be considered as 
a first-line therapy (the decision depends on the location 
and number of lesions) in order to delay the occurrence 
of bleeding or neurological disorders. Radiotherapy of 
the central nervous system may be a part of combined 
therapy during immunotherapy (preferred) and during 
BRAF protein molecularly targeted therapy (II, B). RT 
is also used in palliative therapy in patients with metasta-
ses to soft tissues (ulceration, pain) and to bones (pain).
The advance in therapy of advanced melanoma, 
considering the low efficacy of cytotoxic agents, results 
from the use of nonspecific immunotherapy with use of 
monoclonal antibodies anti-CTLA4 or anti-PD1, which 
inhibit the systemic mechanisms of immunosuppression 
in order to induce an antineoplastic response (activation 
of lymphocytes T) as well as from the use of molecularly 
targeted therapies with use of serine-threonine kinases 
inhibitors (I, A). Patients with advanced melanoma 
should still be referred and screened for prospective 
clinical trials. 
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Dacarbazine is the only registered cytotoxic drug 
for advanced melanoma. Its efficacy is limited (objec-
tive response rate — 15% of patients, median duration 
of response four months) [1, 3]. The only registered 
scheme of dacarbazine therapy is a five-consecutive-day 
schedule with a daily dose of 200 mg/m2; an alterna-
tive schedule of administering a higher dose of a drug 
(850–1000 mg/m2 every three weeks) has not formally 
been accepted; however, this alternative is considered 
useful in clinical practice. Paclitaxel in monotherapy or 
in combination with dacarbazine does not improve the 
duration of the response to the second-line therapy. 
Randomised trials in patients did not confirm higher 
efficacy of a polychemotherapy schedule including dac-
arbazine combined with cisplatin, vinca alkaloids (e.g. 
vinblastine) and nitrosamine derivates (e.g. carmustine) 
and tamoxifen. Use of biochemotherapy (chemotherapy 
combined with interleukin-2 and INF a-2b) does not 
improve melanoma patients’ overall survival rates com-
pared to chemotherapy. The results of clinical studies 
indicate that interleukin-2 in monotherapy or combined 
with IFN a-2b slightly improves the overall response 
rate, with no influence on the overall survival rate. The 
toxicity of this therapy is significant. Currently the use 
of chemotherapy should be limited to lifesaving situa-
tions after failure of the molecularly targeted therapies 
or immunotherapy (I, A).
Immunotherapy
Ipilimumab has been registered in the therapy 
of patients with advanced melanomas and resulted 
in significantly higher overall survival rates (a differ-
ence of about 3.5 months) compared to peptide vaccine 
gp100 in a second-line therapy, with no impact on the 
disease-free progression time [34, 35]. Kinetics and time 
of response duration on ipilimumab therapy are different 
than for classical chemotherapy. The benefit of therapy is 
observed only after 3–4 months of therapy, which limits 
its application to patients with advanced melanoma with 
minimal symptoms, good performance status, and low 
disease course as well as (considering the safety profile) 
to patients with no autoimmune diseases. Due to late 
objective response occurrence, a reliable evaluation of 
the efficacy of ipilimumab therapy should be done after 
12 weeks of treatment. Moreover, in the early phase of 
the therapy a phenomenon of paradoxical progression 
(so-called pseudo progression) due to infiltration of the 
tumours by the immunocompetent cells may occur. The 
immunological response criteria should be applied in 
order to get objective imaging examination evaluation of 
the ipilimumab efficacy [34–36]. Currently there are no 
known predictive factors of response to ipilimumab. A rec-
ommended dosing schedule is 3 mg/kg of body weight, 
administered every three weeks, up to four doses (I, A).
The objective overall response rate to ipilimumab 
therapy is low (about 10%), and long-term benefits are 
observed in a limited number of patients (20–25%); how-
ever, they are characterised by long-lasting responses 
(the longest observation reaches 10 years). Adverse 
events related to autoimmunological reactions con-
stitute a major problem of ipilimumab therapy (grade 
3–4 adverse events occur in about 20–25% of patients). 
The most common immunological adverse events in-
clude: skin changes, colitis (diarrhoea), hepatotoxicity, 
and endocrinopathies (including insufficiency of pitui-
tary and thyroid gland). Occurrence of these syndromes 
in a patient treated with ipilimumab should result in an 
urgent referral of this patient to a medical centre expe-
rienced in treating complications of immunotherapy. 
In the case of intensified symptoms that disenable 
transportation, corticosteroids should be immediately 
administered (prednisolone [or equivalent] 1–2 mg/kg 
of body weight), and further therapy should be applied 
in collaboration with, or with assistance of, a referral 
centre. The appropriate algorithms of proceeding are 
accessible [35] and should be rigorously implemented 
from the moment of the occurrence of first symptoms 
suggesting immunological toxicity. 
Ipilimumab therapy should be applied only in ter-
tiary referral centres that provide holistic diagnostic and 
therapeutic proceedings. It is not recommended that this 
therapy be started in inexperienced centres with limited 
therapeutic options.
Currently, immunotherapy in skin melanomas is 
mostly related to the usage of immune control check-
point PD-1 in monotherapy (nivolumab in fixed does 
240 mg every two weeks or 480 mg every four weeks or 
pembrolizumab 200 mg every three weeks) (I, A) [37–39] 
or in combination with anti-CTLA-4 antibodies (I, B) 
[40]. These agents have been proven in clinical practice, 
in monotherapy or in combination with ipilimumab, to 
give long-lasting clinical benefit in some patient with 
advanced melanomas and significant response rates 
(reaching 50%) and one-year survival rates of 70–80%. 
The use of nivolumab or pembrolizumab results in 
two-year survival rates of 50–60% (median survival ex-
ceeds two years; three-year survival rate reaches about 
45%), with acceptable toxicity (about 15% in grade 3/4, 
which is significantly less than for ipilimumab); however, 
the most severe symptom also results from autoimmune 
toxicity. Clinical studies confirmed a higher efficacy of 
pembrolizumab concerning the overall survival and 
disease-free survival time compared to ipilimumab 
in first-line therapy and compared to chemotherapy 
after failure of prior therapy [37–39]. In recently pub-
lished results of a clinical trial that compared efficacy 
of nivolumab in monotherapy, ipilimumab in mono-
therapy, and a combination of both drugs, nivolumab 
was revealed to be more effective than ipilimumab (the 
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median disease-free survival time reached, respectively, 
6.9 vs. 2.9 months); however, the combination of both 
drugs had the highest efficacy (the median disease-free 
survival was 11.5 months). The combination therapy was 
the best option in the case of low PD-L1 expression in 
the neoplastic tissue (< 5%). In the case of high PD-L1 
expression (> 5%) the results of nivolumab therapy in 
monotherapy or in combination with ipilimumab were 
comparable, as were the overall survival results [40]. 
The results of combined ipilimumab and nivolumab 
therapy were also better when a BRAF gene mutation 
was present; however, in the whole group of patients 
[41] the improvement in three-year survival rates in the 
combination therapy arm compared to monotherapy 
with nivolumab reached only 6%: 58% vs. 52%, respec-
tively. The adverse events in Common Terminology 
Criteria for Adverse Events (CTCAE) grade 3–4 were 
significantly more frequent in the combined therapy arm 
(56.5%) compared to 19% in the nivolumab and 27% 
in the ipilimumab arm. 
In the clinical study a therapy with anti-PD-L1 anti-
body, pembrolizumab, was maximally continued for two 
years. In the group of 104 patients who accomplished the 
two-year therapy period, 102 persons (98%) are still alive 
while the nine-month disease progression-free survival 
rate reached 91% (which means that in the majority of 
patients disease control was maintained even when the 
active therapy had been stopped). Based on available 
literature data, it is now possible to consider discontinu-
ing immunotherapy with anti-PD1 antibodies in patients 
who have an objective response after two years of treat-
ment (CR, PR) / clinical benefit (II, B) [42].
In light of the presented results of the clinical studies, 
ipilimumab should not constitute an essential type of 
immunotherapy in patients with advanced melanomas, 
because it is less efficient than anti PD-L1 antibodies and 
has a worse safety profile. The therapy should be started 
from anti PD-L1 (nivolumab or pembrolizumab) in 
monotherapy (I, A). The issue of combined therapy with 
anti-CTLA-4 antibodies requires further investigation, 
the use of combination of anti-CTLA-4 with ant-PD-1 is 
specifically justified in patients with asymptomatic brain 
metastases to CNS (II, B). 
Molecularly targeted therapy
The presence of mutation of the RAS/RAF/MEK/ERK 
MAP kinase pathway is detected in 75% of skin can-
cers. The major mechanism leading to hyperactivity of 
RAS/RAF/MAPK pathway I skin melanoma is a muta-
tion of a kinase BRAF encoding gene mutation. Somatic 
mutations in BRAF gene are observed in 50–70% of skin 
cancers occurring on skin areas not exposed to long-term 
solar radiation. Published in the year 2011, the results 
of the registration phase III study of vemurafenib use 
in first-line therapy in patients with present BRAF 
V600 mutation showed 48% overall response to therapy 
in patients receiving BRAF inhibitor (BRAFi) com-
pared to 5% in patients on dacarbazine, as well as sig-
nificant improvement of disease progression time (five 
months difference) and of overall survival (three months 
difference) [43]. Vemurafenib has been registered to 
treat patients with advanced melanoma with presence 
of BRAF mutation (testing for this mutation is possible 
in Polish centres with use of a validated test) (I, A). 
Even though in the majority of patients, resistance to 
therapy will develop (median disease progression-free 
survival totals 6–7 months), the results of phase II–III 
revealed a 13–16-month-long median overall survival 
time, in patients with metastatic melanoma, which is 
significantly better than any other reported survival 
benefit in this subset of patients. Vemurafenib is char-
acterised by significant skin toxicity (hypersensitivity to 
UV radiation), hepatotoxicity typical for kinase inhibi-
tors, and by formation of secondary neoplasms (cancer 
or keratoacanthoma of the skin in about 20% of treated 
patients). The secondary skin neoplasms may develop 
within a few weeks after the onset of the therapy with ve-
murafenib. Diagnosis of secondary skin cancers requires 
local therapy but not interrupting the drug. The adverse 
events quite often require reduction of vemurafenib 
dose. In the year 2012 a therapeutic efficacy of another 
BRAF inhibitor, dabrafenib, was proven (characterised 
by efficacy similar to vemurafenib but by a different 
toxicity profile, e.g. lower skin toxicity). The median 
disease progression-free time reached 6.7 months for 
dabrafenib vs. 2.9 months for dacarbazine, whereas 
the median overall survival time on dabrafenib therapy 
reported in the year 2013 reached 18.2 months (I, A) 
[44]. In a phase III trial, the efficacy of MEK inhibitor 
(MEKi) - trametinib has also been confirmed in patients 
with metastatic melanomas harbouring BRAF gene 
mutation (I, B) [45]. The efficacy of MEK inhibitors 
has also been observed in patients with NRAS gene 
mutation [46]. The results of recent studies (COMBI-d, 
COMBI-v, coBRIM and COLUMBUS) showed that in 
patients with metastatic melanomas with BRAF gene 
mutation the use of a combination of BRAF and MEK 
inhibitors (dabrafenib and trametinib or vemurafenib 
with cobimetinib or encorafenib with binimetinib) yields 
better results than monotherapy and no increase of tox-
icity (I, A) [47–51]. The median overall survival time on 
the combination of both drugs was improved to about 
23–33 months and a median disease progression time 
of 12–14 months. The best overall survival is achieved 
in patients with normal LDH activity and serum con-
centration and less than three organs involved with 
metastases. The first two combinations are currently 
accessible in Poland in the Drug Program in the first- or 
second-line therapy in patients with advanced melanoma 
with confirmed presence of BRAF V600 mutation. 
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pends on the initial clinical stage of the disease). How-
ever, we should bear in mind that the relapse may occur 
even 10 years after the primary treatment [55, 56] (Table 
5). The relapse risk is the highest in the first three years 
post therapy. That is why it is recommended that a more 
intense schedule of control exams should be applied in 
this period in order to detect a loco-regional relapse, 
which may be cured by surgery. Assessment of scars 
post primary site excision and post lymphadenectomy 
constitutes the most important part of the observation. 
The evaluation of the regional lymph confluence should 
be done carefully (a possible in-transit dissemination). 
To evaluate the local lymph nodes, we can use palpation 
and ultrasonography. A patient may detect a majority of 
loco-regional relapses, and that is why he/she should be 
trained to make a self-control of the area of the mela-
noma excision and of the regional lymph nodes. There 
are some premises that a less intensive control schedule 
has no negative impact on the survival in patients with 
early melanomas. 
Imaging exams are not recommended in asympto-
matic patients with clinical stage IA–IIA. Imaging exams 
(e.g. CT exam) may be considered in asymptomatic 
patients with clinical stage IIB–IIIC during the first 
2–3 years of follow-up (taking into consideration the 
availability of some new, effective drugs in the therapy 
of disseminated melanomas. The earlier data evaluat-
ing the intensive schedule of the control imaging exams 
demonstrated only a minimal benefit — maximally two 
months prolongation of the overall survival time). Then, 
in patients with clinical symptoms suggesting the pres-
ence of distant metastases (liver enzymes elevation, bone 
pains, neurological symptoms, cough, and weakness) 
detailed imaging diagnostics should be done, with CT, 
MRI, PET-CT, and bone scintigraphy included. 
During the control exams we should carefully check 
not only the area of the primary melanoma lesion but 
also the whole skin surface. Melanoma patients have 
a statistically higher risk of developing a lesion of mela-
noma or of another skin cancer. 
Summary
Excisional biopsy of the suspected pigmented moles, 
which may be early melanomas, is essential to diagnose 
and assess the main risk factors of melanoma (microstag-
ing I). Early diagnosis and removal of melanoma not 
only improves the prognosis but also gives a chance of 
cure in nearly 90% of patients. Usually the pigmented 
changes with transversal axis dimensions not exceeding 
2 cm may be removed in an outpatient clinic during an 
excisional biopsy. The next stages of the proceedings 
include qualification of a patient to a radical, wide scar 
excision with appropriate surgical margins and to senti-
The above-mentioned drugs have a beneficial influ-
ence also in patients with stable and/or asymptomatic 
metastases to the brain, and until now this localisation 
was inaccessible for the systemic therapy of melanoma. 
Patients with melanoma and BRAF gene mutation, 
in whom asymptomatic brain metastases have been 
detected, may receive a first-line therapy with BRAF 
inhibitor (in combination with MEK inhibitor).
A new option of the molecularly targeted therapy 
is to restart the combined therapy with BRAF and 
MEK inhibitors after this therapy has been stopped 
due to disease progression. A phase II study revealed 
that restarting therapy with dabrafenib and trametinib 
resulted in partial remission in eight of 25 patients 
(32%) and in stabilisation of the disease in another 
40% of patients. The median disease progression-free 
time to so-called ‘rechallenge’ reached 4.9 months [52]. 
The analysis of data of 116 patients with advanced 
melanoma, who had received therapy with BRAF in-
hibitor, progressed, and received another therapeutic 
modality, and then were restarted on combined therapy 
with BRAF ± MEK inhibitor, was presented at the 
ASCO meeting in 2017. The median time of treatment 
duration was 9.4 and 7.7 months for the primary and 
reused molecularly targeted therapy, respectively. Af-
ter restarting the use of BRAF ± MEK inhibitors the 
response rate was 43%: complete response rate 3%, 
partial response rate 39%, stabilisation of the disease 
24%, and progression of the disease 30% (no data 4%). 
The median overall survival time form the restart of the 
therapy reached 9.8 months (II, B) [53]. 
BRAF inhibitors (+ MEK inhibitors) induce 
a prompt response and neoplasm control in the major-
ity of patients with advanced melanomas with present 
BRAF gene mutation. However, the response duration is 
limited due to activation of mechanisms of resistance to 
therapy. Due to these characteristics this therapy should 
be considered as a treatment of choice in patients with 
symptomatic disease and/or high tumour mass. There 
are no final data concerning the optimal sequence of 
immunotherapy and molecularly targeted therapy in 
patients with melanomas with presence of BRAF gene 
mutation. However, the activity of BRAF inhibitor is 
maintained after immunotherapy and of immunotherapy 
(anti-PD-L1) after treatment with BRAF inhibitors (Fig. 
3, 4). In rare cases of patients with melanomas carrying 
some KIT gene mutations, the activity of KIT kinase 
inhibitors has been observed (II, B) [54].
Follow-up after therapy completion 
The frequency and type of control examinations as 
well as duration of the observation should be established 
based on the individual disease relapse risk (which de-
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Table 5. Exams recommended in monitoring melanoma patients
Clinical stage of 
melanoma
Type of exam Frequency  
of control exams
Early melanomas after the 
excision of the primary site 
without any metastases to 
the lymph nodes (clinical 
stages IA–IB)
Physical examination and anamnesis, especially a careful examination of 
the whole skin surface and of the regional lymph nodes as well as of the 
area of the scare post excision of melanoma
Radiologic image (RT) of the chest — optionally 
Other exams (e.g. US, CT) in the case of presence of suspected symptoms
Ultrasound of regional nodes when no sentinel node biopsy has been 
performed, in skin melanomas ≥ pT1b
There are no indications for any additional test except for physical exam 
in patients post excision of melanoma pT1a
Patients should be trained to perform a self-control examination
Every 6–12 months during 
the first 5 years, then 
once a year (follow-up 
may be done outside the 
specialist centre)
Locally advanced 
melanomas post excision 
of the primary site without 
metastases to regional 
lymph nodes (clinical stages 
IIA–IIC)
Physical examination and anamnesis, especially a careful examination of 
a whole skin surface and of the regional lymph nodes as well as of the 
area of the scare post excision of melanoma
Radiologic image (RT) of the chest, ultrasound of the abdomen
Blood morphology and biochemistry (liver tests and activity of lactate 
dehydrogenase) — optionally 
Other tests (e.g. CT) in the case of presence of suspected symptoms 
Ultrasound of regional nodes when no sentinel node biopsy has been 
performed, in skin melanomas ≥ pT1b
In patients with clinical stage IIB–IIC a CT exam may be done every 
6–12 months and optionally MRI of CNS once a year (during the first 
2–3 years)
Patients should be trained to perform a self-control examination.  
In clinical stage IIC more intensive monitoring schedules may be used  
as in clinical stage III
Every 3–6 months during 
first 2–3 years, then every 
6–12 month during next 
5 years, and then once 
a year
Post excision of the 
metastases to the regional 
lymph nodes or of a local 
relapse/satellite or in-transit 
lesion (clinical stages 
IIIA–IIID) or observation 
after detection of metastasis 
to the sentinel lymph node 
without complementary 
lymphadenectomy
Physical examination and anamnesis. Especially a careful examination of 
a whole skin surface and of the regional lymph nodes as well as of the 
area of the scare post excision of melanoma
Radiologic image (RT) of the chest
Blood morphology and biochemistry (liver tests and activity of lactate 
dehydrogenase) — optionally
Ultrasound examination of lymphatic drainage every 4–6 months in case 
of finding a positive sentinel node without performing lymphadenectomy
Ultrasound of abdomen and eventually of the regions of the removed 
lymph nodes
CT exam of the chest, abdomen, and pelvis every 6–12 months and 
optionally in clinical stage IIIC/IIID, once a year a MRI of the brain (during 
the first 3 years)
Patients should be trained to perform a self-control examination
Every 3–4 months during 
the first 2 years, every 
3–6 month during the next 
3 years, and then once 
a year
After therapy of distant 
metastases (clinical stage IV)
Evaluation of the imaging exams depending on the localisation of the 
measurable metastatic sites
Serum activity of LDH
An individual monitoring 
schedule for each patient
US — ultrasonography; CT — computed tomography; MR — magnetic resonance; LDH — lactate dehydrogenase
nel node procedure. In the case of clinical metastases to 
the regional lymph nodes a radical lymphadenectomy is 
a method of choice. It is recommended that patients with 
high-risk melanoma be included in prospective clinical 
trials evaluating the adjuvant therapy. A schedule of 
diagnostic and therapeutic recommendations in patients 
with skin melanoma is shown in Figure 3–4.
The presence of distant metastases is still associated 
with poor prognosis. It is recommended that patients 
with generalised disease be treated in clinical tri-
als. BRAF mutation should be tested in all patients with 
advanced disease or with high disease relapse risk (III). 
Long-term survival is seen mostly in patients in clinical 
stage IV, who have had resection of singular metastatic 
lesions. In patients with present BRAF V600 gene mu-
tation, mostly in first-line therapy, a BRAF inhibitor 
may be used (preferentially in combination with MEK 
inhibitor). Immunotherapy with anti PD-1 antibodies 
(nivolumab or pembrolizumab) or alternatively ipili-
mumab (anti-CTLA-4 antibody in monotherapy or in 
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Advanced melanoma in stage IV 
or unresectable III
Uncontrolled, symptomatic brain 
metastases, ECOG > 2
Individual management
BRAF(+)
Nivolumab
Pembrolizumab
Nivolumab + ipilimumab PDL1(–)? 
Nivolumab
Pembrolizumab
Nivolumab + ipilimumab PDL1(–)? 
iBRAF + iMEK Ipilimumab, chemotherapy
Ipilimumab, BRAFi + MEKi, 
chemotherapy 
Ipilimumab, chemotherapy
BRAF(–)
BRAFi + MEKi*
Pembrolizumab 
Nivolumab  
Nivolumab + ipilimumab PDL1(–)? 
?Indication registered but not reimbursed
*dabrafenib + trametinib, vemurafenib + cobimetinib; or encorafenib + binimetinib
Advanced melanoma clinical 
stage IV, C43 or unresectable III 
 BRAFi + MEKi
Pembrolizumab
Nivolumab
Nivolumab+ipilimumab PDL1(–)?
Ipilimumab, chemotherapy
BRAFi + MEKi BRAFi + MEKi
Ipilimumab, chemotherapy
 BRAFi + MEKi/ipilimumab
Pembrolizumab
Nivolumab
Nivolumab+ipilimumab PDL1(–)?
Figure 3. Recommended schedule of systemic therapy in patients with advanced melanoma in clinical stage IV or unresectable III. 
BRAFi — BRAF inhibitor; MEKi — MEK inhibitor
Figure 4. Recommended schedule of systemic therapy in patients with advanced melanoma in clinical stage IV or unresectable 
III with present BRAF gene mutation. BRAFi — BRAF inhibitor; MEKi — MEK inhibitor
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combination with anti-PD-1) may be used independently 
of the BRAF mutation presence. The optimal sequence 
of therapy (especially in the case of BRAF mutation) has 
not been assessed. The use of combined therapy with 
BRAF and MEK inhibitors involves a high response 
rate (about 70%) and rapid alleviation of symptoms of 
the disease. Therapy with anti-PD-1 antibodies results 
in lower response rates, but in the majority of patients 
the response is durable.
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